X
[{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Reports Positive Top-Line CAN106 Phase 1 Data Receives Approval to Treat Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Phase 1b\/2 Trial in China Results Suggest Complete Blockade of Complement Function CAN106 Safe and Well-Tolerated","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Clover Biopharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
In pre-clinical studies, SCB-219M has demonstrated an extended serum half-life and favorable pharmacokinetics /pharmacodynamics (PK/PD) profile that supports weekly dosing possibility of the drug.
Lead Product(s):
SCB-219M
Therapeutic Area: Hematology
Product Name: SCB-219M
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 14, 2022
Details:
CAN106 is a long-acting, recombinant human mAB that specifically binds to and neutralizes C5 in the complement system, C5 is a validated mechanism of action in numerous hematology, nephrology, and neurology diseases, for treatment of multiple complement-mediated disorders.
Lead Product(s):
CAN106
Therapeutic Area: Hematology
Product Name: CAN106
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 12, 2022
Details:
CAN106 is a novel, long-acting recombinant human monoclonal antibody. CAN106 has demonstrated a favorable PK/PD profile, safety, and tolerability, indicating that CAN106 has the potential to effectively inhibit C5 in patients with certain complement-mediated diseases.
Lead Product(s):
CAN106
Therapeutic Area: Hematology
Product Name: CAN106
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 07, 2022
Details:
CANbridge is developing CAN106 for the treatment of multiple diseases associated with complement dysregulation, including PNH. CAN106 comes out of the strategic partnership between CANbridge and WuXi Biologics in collaboration with Privus Biologics.
Lead Product(s):
CAN106
Therapeutic Area: Hematology
Product Name: CAN106
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
WuXi Biologics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 15, 2021
Details:
CAN106 is a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 and is intended to prevent the formation of membrane attack complexes on red blood cell surfaces, thereby reducing cell lysis and other symptoms associated with PNH.
Lead Product(s):
CAN106
Therapeutic Area: Hematology
Product Name: CAN106
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
WuXi Biologics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 10, 2021